Recurrent Astrocytoma, IDH-Mutant

specific

The reemergence of IDH-mutant astrocytoma after a period of remission.

17

Centers

17

Active Trials

—

Cancer Funding

Top Centers for Recurrent Astrocytoma, IDH-Mutant(17)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
Siteman Cancer CenterSt. Louis, MO
NCI Comprehensive
Active Research Program
52.9
2
Yale Cancer Center Yale School of MedicineNew Haven, CT
NCI Comprehensive
Active Research Program
52.9
3
Vanderbilt-Ingram Cancer CenterNashville, TN
NCI Comprehensive
Active Research Program
52.9
4
Herbert Irving Comprehensive Cancer CenterNew York, NY
NCI Comprehensive
Active Research Program
52.9
5
UC San Diego Moores Cancer CenterLa Jolla, CA
NCI Comprehensive
Active Research Program
52.9
6
Laura and Isaac Perlmutter Cancer Center at NYU Langone HealthNew York, NY
NCI Comprehensive
Active Research Program
52.9
7
Winship Cancer InstituteAtlanta, GA
NCI Comprehensive
Active Research Program
52.9
8
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH
NCI Comprehensive
Active Research Program
52.9
9
University of Wisconsin Carbone Cancer CenterMadison, WI
NCI Comprehensive
Active Research Program
52.9
10
City of Hope Comprehensive Cancer CenterDuarte, CA
NCI Comprehensive
Active Research Program
52.9
11
UC Davis Comprehensive Cancer CenterSacramento, CA
NCI Comprehensive
Active Research Program
52.9
12
University of Virginia Cancer CenterCharlottesville, VA
NCI Comprehensive
Active Research Program
52.9
13
Sylvester Comprehensive Cancer CenterMiami, FL
NCI Clinical
Active Research Program
52.9
14
UCI Chao Family Comprehensive Cancer CenterOrange, CA
NCI Comprehensive
Active Research Program
52.9
15
VCU Massey Comprehensive Cancer CenterRichmond, VA
NCI Comprehensive
Active Research Program
52.9
16
University of Illinois Cancer CenterChicago, IL
Active Research Program
52.9
17
Cancer Center at IllinoisUrbana, IL
Active Research Program
52.9

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →